Literature DB >> 6808516

Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase.

D A Carson, D B Wasson, E Lakow, N Kamatani.   

Abstract

An inherited deficiency of adenosine deaminase (Ado deaminase; adenosine aminohydrolase, EC 3.5.4.4) causes severe combined immunodeficiency disease in humans. A similar deficiency in purine nucleoside phosphorylase (Puo phosphorylase; purine-nucleoside:orthophosphate ribosyltransferase, EC 2.4.2.1) engenders a selective cellular immune deficit. To elucidate the possible metabolic basis for the contrasting immunologic phenotypes, we compared the toxicity toward mature resting human lymphocytes of the Ado deaminase substrates deoxyadenosine and adenosine and the Puo phosphorylase substrate deoxyguanosine. When Ado deaminase was inhibited, micromolar concentrations of deoxyadenosine progressively killed nondividing helper and suppressor-cytotoxic T cells, but not B cells. The toxicity required phosphorylation, with subsequent dATP formation. The deoxyadenosine analogs 2-chlorodeoxyadenosine, 2-fluorodeoxyadenosine, and adenine arabinonucleoside also killed resting T cells. Cell death was unrelated to inhibition of adenosylhomocysteinase (EC 3.3.1.1) but was preceded by a gradual decline in ATP levels. As much as 1 mM deoxyguanosine did not impair resting lymphocyte viability, despite the synthesis of dGTP. The combination of 200 microM adenosine plus 500 microM homocysteine thiolactone killed dividing lymphocytes but had no discernible toxic effect toward resting T cells, which accumulated adenosylhomocysteine over a 4-hr period but thereafter excreted the nucleoside into the culture medium. The different clinical syndromes associated with genetic deficiencies of Ado deaminase and Puo phosphorylase may be explained by the ability of dATP to kill mature resting T lymphocytes by depleting ATP levels.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6808516      PMCID: PMC346525          DOI: 10.1073/pnas.79.12.3848

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s).

Authors:  D A Carson; J Kaye; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  Formation of 5'-nucleotides of 6-methylmercaptopurine ribonucleoside in human tissues in vitro.

Authors:  T P Zimmerman; L C Chu; C J Buggé; D J Nelson; R L Miller; G B Elion
Journal:  Biochem Pharmacol       Date:  1974-10-01       Impact factor: 5.858

3.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

4.  Evidence for control of several different tissue-specific isozymes of adenosine deaminase by a single genetic locus.

Authors:  R Hirschhorn; V Levytaka; B Pollara; H J Meuwissen
Journal:  Nat New Biol       Date:  1973-12-19

5.  Enhancement by irradiated T cells of human plasma cell production: dissection of helper and suppressor functions in vitro.

Authors:  F P Siegal; M Siegal
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

6.  The T cell dependence of B cell differentiation induced by pokeweed mitogen.

Authors:  R G Keightley; M D Cooper; A R Lawton
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

7.  Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency.

Authors:  M S Coleman; J Donofrio; J J Hutton; L Hahn; A Daoud; B Lampkin; J Dyminski
Journal:  J Biol Chem       Date:  1978-03-10       Impact factor: 5.157

8.  Effect of adenosine deaminase inhibition upon human lymphocyte blastogenesis.

Authors:  D A Carson; J E Seegmiller
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

9.  Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity.

Authors:  E R Giblett; A J Ammann; D W Wara; R Sandman; L K Diamond
Journal:  Lancet       Date:  1975-05-03       Impact factor: 79.321

10.  Sheep red cell binding to human lymphocytes treated with neuraminidase; enhancement of T cell binding and identification of a subpopulation of B cells.

Authors:  Z Bentwich; S D Douglas; E Skutelsky; H G Kunkel
Journal:  J Exp Med       Date:  1973-06-01       Impact factor: 14.307

View more
  20 in total

1.  Six-layer structure for genomics and its applications.

Authors:  Naoyuki Kamatani
Journal:  J Hum Genet       Date:  2015-11-12       Impact factor: 3.172

2.  Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.

Authors:  S Seto; C J Carrera; M Kubota; D B Wasson; D A Carson
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

3.  Mechanisms of 2'-deoxyguanosine toxicity in mouse T-lymphoma cells with purine nucleoside phosphorylase deficiency and resistance to inhibition of ribonucleotide reductase by dGTP.

Authors:  D S Duan; T Nagashima; T Hoshino; F Waldman; K Pawlak; W Sadee
Journal:  Biochem J       Date:  1990-06-15       Impact factor: 3.857

4.  Repeated pentostatin (2'deoxycoformycin)-induced remissions in a patient with advanced chronic lymphocytic leukemia.

Authors:  R O Dillman; A L Yu; C N Qiao
Journal:  West J Med       Date:  1988-03

Review 5.  Adenosine and adenosine receptors in immune function. Minireview and meeting report.

Authors:  R B Gilbertsen
Journal:  Agents Actions       Date:  1987-10

Review 6.  Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

7.  Relative sensitivity of human T cell subsets to deoxyadenosine toxicity.

Authors:  R E Callard; T M Ewing; R M Fox
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

8.  Adenine ribo- and deoxyribonucleotide metabolism in human erythrocytes, B- and T-lymphocyte cell lines, and monocyte-macrophages.

Authors:  W N Valentine; D E Paglia; S Clarke; B H Morimoto; M Nakatani; R Brockway
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

9.  Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.

Authors:  D A Carson; D B Wasson; E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

Review 10.  Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.